Phase 3 Neck Clinical Trials
53 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 53 trials
Recruiting
Phase 3
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Metastatic Head and Neck Squamous Cell CarcinomaStage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Recurrent Head and Neck Squamous Cell Carcinoma+18 more
National Cancer Institute (NCI)158 enrolled177 locationsNCT06589804
Recruiting
Phase 3
Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer
Advanced Head and Neck Cancer
Canadian Cancer Trials Group196 enrolled8 locationsNCT06641791
Recruiting
Phase 3
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC500 enrolled186 locationsNCT07276399
Recruiting
Phase 3
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
Head and Neck Squamous Cell Carcinoma
Merus B.V.600 enrolled216 locationsNCT06496178
Recruiting
Phase 3
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Head and Neck Squamous Cell Carcinoma
Merus B.V.700 enrolled205 locationsNCT06525220
Recruiting
Phase 2Phase 3
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma
Bicara Therapeutics650 enrolled173 locationsNCT06788990
Recruiting
Phase 3
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
Oligometastatic Squamous Cell Carcinoma of the Head and Neck
European Organisation for Research and Treatment of Cancer - EORTC200 enrolled30 locationsNCT05815927
Recruiting
Phase 2Phase 3
Trop2-targeted immunoPET Imaging of Solid Tumors
Liver CancerOvarian CancerCervical Cancer+11 more
RenJi Hospital400 enrolled1 locationNCT06851663
Recruiting
Phase 3
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Neoplasms, Head and Neck
GlaxoSmithKline864 enrolled277 locationsNCT06256588
Recruiting
Phase 2Phase 3
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Unresectable Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck CancerRecurrent Head and Neck Cancer
BioNTech SE350 enrolled195 locationsNCT04534205
Recruiting
Phase 3
Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Groupe Oncologie Radiotherapie Tete et Cou780 enrolled1 locationNCT07264075
Recruiting
Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
HPV-unrelated Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine81 enrolled5 locationsNCT04966481
Recruiting
Phase 3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Locally Advanced Head and Neck Squamous Cell Carcinoma
AstraZeneca1,145 enrolled305 locationsNCT06129864
Recruiting
Phase 3
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Head and Neck Squamous Cell CarcinomaStage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8+2 more
Alliance for Clinical Trials in Oncology228 enrolled200 locationsNCT06992427
Recruiting
Phase 2Phase 3
Trial Evaluating Hypo-fractionated Accelerated Versus Conventional Fractionated Adjuvant RT in Head & Neck Malignancies
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
All India Institute of Medical Sciences369 enrolled1 locationNCT07573956
Recruiting
Phase 3
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Eyelid Squamous Cell Carcinoma+17 more
National Cancer Institute (NCI)420 enrolled206 locationsNCT06568172
Recruiting
Phase 3
CARES (Comprehensive Analgesic, Recovery, and Education Support) for Surgery Trial
Opioid misuseChronic PainBack Pain+1 more
Stanford University375 enrolled4 locationsNCT06027099
Recruiting
Phase 2Phase 3
A Trial Evaluating Omission of Radiotherapy to Regional Lymphatic's
Head and Neck Cancer
All India Institute of Medical Sciences396 enrolled1 locationNCT07528495
Recruiting
Phase 3
The SWOAR Trial Sparing of Swallowing and Aspiration Related Organs at Risk & Submandibular Gland With Intensity Modulated Radiotherapy Versus Standard IMRT in Head and Neck Squamous Cell Carcinomas
Head and Neck NeoplasmsSwallowing Sparing IMRT
All India Institute of Medical Sciences136 enrolled1 locationNCT05187091
Recruiting
Phase 3
Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
Oropharynx CancerLarynx CancerHypopharynx Cancer+1 more
Centre Leon Berard460 enrolled8 locationsNCT06706401